Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
Net loss: US$132.1m (loss widened by 49% from FY 2023). US$1.71 loss per share (further deteriorated from US$1.27 loss in FY 2023). ACRS Products In Clinical Trials Phase II: 5. NasdaqGS:ACRS Earnings and Revenue Growth March 4th 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Aclaris Therapeutics Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) missed analyst estimates by 122%. The company's shares are down 5.3% from a week ago. Risk Analysis Before you take the next step you should know about the 3 warning signs for Aclaris Therapeutics (2 are concerning!) that we have uncovered. Have feedback on this article? Concerned about the
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $15.00 price target on the stock.MarketBeat
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Aclaris Therapeutics to Participate in Two March Healthcare Conferences [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics to Participate in Two March Healthcare ConferencesGlobeNewswire
- Seborrheic Keratosis Global Clinical Trials Market Review 2025, Competitive Analysis of Aclaris Therapeutics, DermBiont, EpiPharm, BioLineRx, DermResearch, LEO Foundation, maxingvest, Novartis [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 2/27/25 - Miss
ACRS
Sec Filings
- 3/10/25 - Form EFFECT
- 3/4/25 - Form 4
- 3/4/25 - Form 4
- ACRS's page on the SEC website